Suva, Mario Luca
- Massachusetts General Hospital · Pathology (investigator's affiliation)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #11,171
- R01 Holder
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2020 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$930.8K
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#11,171
By linked amount among FY2023 PIs
Earliest Year Loaded
2020
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Suva, Mario Luca as a PI. Multi-PI records show the full award amount for context.
- 5R01CA258763-03R01Contact PIDeciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omicsMassachusetts General Hospital · Pathology (investigator's affiliation)$546.9Kaward amount
- 5R37CA245523-04R37Contact PIDissecting the cellular hierarchies of malignant gliomas by single-cell functional genomicsMassachusetts General Hospital · Pathology (investigator's affiliation)$383.9Kaward amount
Award organization
Organizations that administered FY2023 awards listing Suva, Mario Luca as a PI.
FY2023 award administered by Massachusetts General Hospital (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2020First NIH AwardMassachusetts General Hospital
- 2020$500K Cumulative Funding
- 2021$1M Cumulative Funding
- 2021Entered Top 50% NationallyRanked #9729
- 2021R01 Grant Holder
- 2022$2M Cumulative Funding